Off-the-shelf Immune Drug for Aggressive Multiple Myeloma: Teclistamab

0:00 - Introduction
1:06 - What is Teclistamab and how does it tackle myeloma cells?
4:06 - Preliminary findings about efficacy, durability and toxicity of Teclistamab
9:19- Advantages and disadvantages of bispecific antibodies compared to CAR T cell therapy?
15:33 - Could bispecific antibodies be a bridge to Car T cells?
22:44 - Side-effects and cost of Teclistamab compared to CAR T cell therapy?
28:07 - How is Teclistamab administered?
29:02 - What is BCMA and why is it a target for Teclistamab?
34:30 - Will bispecific antibody therapy leave the patient immunocompromised?
37:10 - Do you think IVIG infusions now contain some covid antibodies too?
37:42 - Does the success of Bispecific Antibody Therapy depend on the status of the patient’s T cells?
41:42 - Could a patient get a T Cell infusion before they get treated?
44:08 - Finding the most effective bispecific antibody for different types of myeloma?
46:42 - Is step dosing done in the other bispecifics as well? Is step dosing expected to be part of the final recommended dose scheduling for Teclistamab?
47:40 - Is it possible to create an oral therapy of bispecifics given that it's an antibody?

U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for teclistamab in the treatment of relapsed or refractory multiple myeloma. This follows a PRIME (PRIority MEdicines) designation from the European Medicines Agency (EMA) received earlier this year.

The Breakthrough and PRIME designations are supported by data from the Phase 1 MajesTEC-1 study, an open-label, multicenter clinical trial evaluating the safety and efficacy of teclistamab in adults with measurable multiple myeloma that is relapsed or refractory to established therapies or be intolerant of those established multiple myeloma therapies.

Multiple Myeloma that has relapsed and has become refractory to treatment, represents a patient population with unmet needs. Teclistamab is a bispecific IgG4 antibody that binds BCMA and CD3 to redirect T cells to multiple myeloma cells. According to the investigators, the current study is—to their knowledge—the first report of a T-cell–redirecting bispecific antibody for the treatment of patients with cancer.

The Myeloma panel of Gary Petersen, Jack Aiello, and Cynthia Chmielewski takes a deep dive on Teclistamab with Dr. Alfred L. Garfall hematologist oncologist from University of Pennsylvania.

#teclistamab #multiplemyeloma #cancerresearch #mmsm

SUBSCRIBE!

LET'S CONNECT!

Disclaimer: This video is provided solely for informational purposes. The opinions expressed in this video do not necessarily reflect the views of CureTalks. The video does not constitute medical advice, and is not intended for use in the diagnosis or treatment of individual patients or conditions, or as a substitute for consultation with a licensed medical professional.